zileuton

Drug Overview

In the specialized field of Pulmonology, treating chronic airway inflammation requires a variety of approaches to accommodate different patient profiles and disease mechanisms. Zileuton is a unique and highly effective oral medication classified within the 5-Lipoxygenase Inhibitor drug class. Unlike rescue medications that simply open the airways temporarily, this medicine provides long-term, foundational support for patients struggling with persistent respiratory conditions.

Zileuton is designed to be taken daily to prevent asthma attacks before they start. By acting on specific chemical pathways in the body that cause inflammation and mucus buildup, it serves as an excellent maintenance option for patients who may not fully respond to a standard Inhaled Corticosteroid (ICS) or who have specific types of allergic asthma. It helps patients achieve stable lung function and reduces the daily burden of chronic respiratory failure.

• Generic Name: Zileuton
• US Brand Names: Zyflo, Zyflo CR (Controlled Release)
• Route of Administration: Oral (Tablet)
• FDA Approval Status: FDA-approved for the prophylaxis (prevention) and chronic treatment of asthma in adults and children 12 years of age and older.

What Is It and How Does It Work? (Mechanism of Action)

To understand how zileuton works, it is helpful to explore the body’s inflammatory response. When a person with asthma breathes in a trigger—like cold air, pollen, or smoke—the immune system reacts defensively. A key part of this reaction involves a fatty acid in the body called arachidonic acid.

The mechanism of action for zileuton involves the direct inhibition of the 5-lipoxygenase enzyme. In a typical asthma response, the 5-lipoxygenase enzyme converts arachidonic acid into potent inflammatory chemicals known as leukotrienes (specifically LTB4, LTC4, LTD4, and LTE4). These leukotrienes are responsible for a cascade of severe respiratory symptoms: they cause the smooth muscles around the airways to constrict, prompt the blood vessels to leak fluid (causing airway swelling), and trigger the glands to produce thick, sticky mucus.

By blocking the 5-lipoxygenase enzyme, zileuton stops the production of all these leukotrienes at the very source. Because it completely halts the assembly line of these inflammatory chemicals, it prevents the subsequent airway narrowing, edema (swelling), and mucus hypersecretion. This provides a deep, physiological level of asthma control, keeping the bronchial tubes open and clear throughout the day and night.

FDA-Approved Clinical Indications

Primary Indication

The primary FDA-approved indication for zileuton is the Prophylaxis and chronic asthma treatment. It is intended to be used every day to prevent asthma symptoms and reduce the frequency of severe asthma attacks in patients 12 years and older.

Other Approved & Off-Label Uses

While officially approved for asthma, pulmonologists occasionally utilize this medication for other conditions driven by leukotriene overproduction:

• Aspirin-Exacerbated Respiratory Disease (AERD): Used frequently off-label for this specific asthma phenotype, where patients experience severe asthma attacks and nasal polyps after taking aspirin or NSAIDs.
• Allergic Rhinitis: Sometimes used off-label to manage severe seasonal allergies that directly trigger asthma symptoms.
• Nasal Polyposis: Investigated for reducing the size and recurrence of nasal polyps related to chronic sinus inflammation.

Primary Pulmonology Indications

• Improve Ventilation: By stopping the production of mucus and reducing tissue swelling, the drug keeps the inner diameter of the airways wide open, allowing for easier and deeper breathing.
• Reduce Exacerbations: Consistent daily use of this medication drastically lowers the likelihood of sudden, severe asthma attacks, helping patients avoid emergency room visits and hospital stays.
• Slow the Decline of Lung Function: Chronic inflammation can lead to permanent scarring in the lungs. By stopping leukotriene production, zileuton helps protect the long-term elasticity and health of the airway walls.

Dosage and Administration Protocols

Zileuton is an oral tablet that must be taken consistently to maintain its protective effects in the bloodstream. It is a long-acting controller medication, not a quick-acting Bronchodilator.

Specific Patient Population Adjustments:

• Hepatic Impairment: Zileuton is absolutely contraindicated in patients with active liver disease or transaminase elevations greater than or equal to three times the upper limit of normal.
• Pediatrics: It is not recommended for children under 12 years of age due to a lack of established safety data.
• Elderly Patients: Standard dosing applies, but liver function must be monitored with extra vigilance.

Note: Accuracy is critical to differentiate between short-acting rescue therapies and daily maintenance therapies. Zileuton will not stop an asthma attack that has already started.

“Dosage must be individualized by a qualified healthcare professional.”

Clinical Efficacy and Research Results

2020–2026 clinical research shows zileuton, a 5-lipoxygenase inhibitor, as an add-on or alternative therapy for difficult asthma, especially AERD. It improves FEV1 by 10–15% within a month and reduces exacerbations, lowering steroid use by 30–40% annually. Patients also show better exercise tolerance, improved 6MWD, fewer symptoms, reduced rescue inhaler use, and overall improved quality of life. 

Safety Profile and Side Effects

Black Box Warning

There is NO “Black Box Warning” for zileuton. However, there is a very prominent and critical clinical warning regarding Hepatotoxicity (liver toxicity). Zileuton can cause significant elevations in liver enzymes, and careful medical supervision is mandatory.

Common Side Effects (>10%)

• Headache
• Upset stomach (dyspepsia)
• Nausea
• Muscle aches (myalgia)
• Throat pain or sinusitis

Serious Adverse Events

• Hepatotoxicity: Liver damage is the most serious risk. Signs include yellowing of the skin or eyes (jaundice), severe fatigue, right-sided abdominal pain, and dark urine.
• Neuropsychiatric Events: Like other drugs that modify leukotrienes, zileuton has been associated with mood or behavior changes, including sleep disorders, vivid dreams, anxiety, or depression.
• Paradoxical Bronchospasm: Though incredibly rare with oral medications, an unexpected tightening of the airways can occur.

Management Strategies

• Liver Monitoring: This is the most crucial management strategy. Doctors must perform blood tests to check liver enzymes before starting the drug, once a month for the first three months, every two to three months for the rest of the first year, and periodically thereafter.
• Rescue Inhaler Use: Patients must always carry a fast-acting rescue inhaler (such as albuterol) to manage sudden asthma attacks.
• Symptom Reporting: Patients should be instructed to stop the medication and contact their doctor immediately if they notice signs of liver stress or unusual changes in their mood or behavior.

Research Areas

Direct Clinical Connections

Active pulmonology research (2024–2026) is examining leukotriene inhibitors like zileuton and their role in airway remodeling. Chronic asthma can cause smooth muscle thickening and structural airway changes, and studies are assessing whether 5-lipoxygenase inhibition can halt or reverse this process. Research also evaluates improved mucociliary clearance, as reduced leukotriene-driven mucus may enhance ciliary function and pollutant removal.

Advancements focus on novel delivery systems, including extended-release formulations for once-daily dosing, alongside broader access through generics. In precision medicine, biologic phenotyping using blood or urinary leukotriene markers helps identify responders, enabling targeted oral therapy for patients with leukotriene-driven asthma and reducing progression to severe disease.

Clinical disclaimer

Information suggesting potential benefits in airway remodeling, mucociliary clearance, precision phenotyping, or other disease-modifying effects should be treated as investigational unless supported by direct clinical evidence. These concepts may be scientifically plausible and actively studied, but they should not be presented as established clinical outcomes without robust data.

Patient Management and Clinical Protocols

Pre-treatment Assessment

• Baseline Diagnostics: Comprehensive Spirometry (PFTs) is required to establish the baseline severity of airway obstruction. Pulse Oximetry (SpO2) is used to evaluate resting oxygen saturation.
• Organ Function: Baseline hepatic monitoring is absolutely mandatory. Liver enzyme tests (ALT and AST) must be drawn and reviewed to ensure the patient’s liver is entirely healthy before initiating therapy.
• Specialized Testing: Allergy skin testing or Fractional Exhaled Nitric Oxide (FeNO) tests can help physicians confirm if the patient has an inflammatory asthma profile that will respond well to leukotriene inhibition.
• Screening: A thorough review of all current medications, as zileuton can interact with several common drugs, including the blood thinner warfarin and the asthma drug theophylline.

Monitoring and Precautions

• Vigilance: Doctors monitor asthma symptom control using standardized questionnaires like the Asthma Control Test (ACT). Regular, scheduled blood tests for liver function must be adhered to strictly.
• Lifestyle: Smoking cessation is an absolute requirement, as smoking highly damages the airway lining and reduces the effectiveness of pulmonary medications. Patients must also actively avoid known environmental triggers like pollen, cold air, and pollution.
• Vaccination: Patients with chronic respiratory conditions must stay current on Flu and Pneumonia vaccinations to prevent severe viral or bacterial infections that can trigger life-threatening asthma exacerbations.

“Do’s and Don’ts” list

• DO take the extended-release (CR) tablets within one hour after your morning and evening meals.
• DO attend all scheduled appointments for your liver blood tests.
• DO contact your doctor immediately if you experience extreme fatigue, nausea, or yellowing of your skin.
• DO continue to carry your fast-acting rescue inhaler everywhere you go.
• DON’T stop taking the medication just because your breathing feels better; it works by preventing future inflammation.
• DON’T chew, crush, or cut the extended-release tablets; they must be swallowed whole.
• DON’T use zileuton to treat a sudden asthma attack; it will not work fast enough to relieve acute bronchospasm.

Legal Disclaimer

The medical information provided in this guide is intended for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare professional, Pulmonologist, or pharmacist regarding any questions or concerns you may have about a medical condition, treatment plan, or medication interactions. Never disregard professional medical advice or delay seeking it because of information you have read on this website.